BRPI0411944A - specific human antibodies - Google Patents
specific human antibodiesInfo
- Publication number
- BRPI0411944A BRPI0411944A BRPI0411944-4A BRPI0411944A BRPI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A
- Authority
- BR
- Brazil
- Prior art keywords
- present
- antibodies
- antibody
- administering
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
"ANTICORPOS HUMANOS ESPECìFICOS". A presente invenção fornece anticorpos que se ligam a um epitopo do PSGL-1 que consiste no motivo D-X-Y-D, em que X representa qualquer aminoácido ou a ligação co-valente entre D e Y, e Y é sulfatado, o anticorpo pode ser complexado com uma ou mais cópias de um agente. Os anticorpos da invenção podem ser usados em um método de indução de citotoxicidade de célula dependente de anticorpo e/ou estímulo de células assassinas naturais (NK) ou células T. Além disso, administrando esses anticorpos a um paciente necessitado, é fornecido um método de indução à morte da célula. Também é fornecido um método de prevenção de infecção por um vírus (por ex., HIV), administrando a um paciente um anticorpo da presente invenção. A presente invenção também fornece um método de introdução de um agente em uma célula que expresse PSGL-1 sulfatado, unindo ou complexando um agente a um anticorpo da presente invenção e administrando o complexo à célula. Por fim, a presente invenção fornece métodos de diagnósticos, prognóstico e estadiamento usando os anticorpos presentes."SPECIFIC HUMAN ANTIBODIES". The present invention provides antibodies that bind to a PSGL-1 epitope consisting of the DXYD motif, where X represents any amino acid or the co-valent bond between D and Y, and Y is sulfated, the antibody may be complexed with a or more copies of an agent. The antibodies of the invention may be used in a method of inducing antibody-dependent cell cytotoxicity and / or stimulating natural killer cells (NK) or T cells. In addition, by administering such antibodies to a patient in need, a method of induction of cell death. Also provided is a method of preventing infection by a virus (e.g., HIV) by administering to a patient an antibody of the present invention. The present invention also provides a method of introducing an agent into a sulfated PSGL-1 expressing cell by attaching or complexing an agent to an antibody of the present invention and administering the complex to the cell. Finally, the present invention provides diagnostic, prognostic and staging methods using the present antibodies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61084003A | 2003-06-30 | 2003-06-30 | |
PCT/US2004/021099 WO2005005455A2 (en) | 2003-06-30 | 2004-06-30 | Specific human antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411944A true BRPI0411944A (en) | 2007-01-02 |
Family
ID=34062326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411944-4A BRPI0411944A (en) | 2003-06-30 | 2004-06-30 | specific human antibodies |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1646401A4 (en) |
JP (1) | JP2007527393A (en) |
KR (1) | KR20060107501A (en) |
CN (1) | CN1897970A (en) |
AU (1) | AU2004256113A1 (en) |
BR (1) | BRPI0411944A (en) |
CA (1) | CA2531283A1 (en) |
IL (1) | IL172511A0 (en) |
MX (1) | MXPA06000253A (en) |
RU (1) | RU2006102571A (en) |
WO (1) | WO2005005455A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070298034A9 (en) * | 2005-12-09 | 2007-12-27 | Angela Widom | Sulfotyrosine specific antibodies and uses therefor |
US20070160601A1 (en) * | 2005-12-09 | 2007-07-12 | Angela Widom | Neutralizing antibodies against primate psgl-1 and uses therefor |
FR2894983B1 (en) * | 2005-12-16 | 2012-08-17 | Lab Francais Du Fractionnement | ANTIBODY CHARACTERIZATION TEST. |
RU2475500C2 (en) * | 2007-09-13 | 2013-02-20 | Деленекс Терапьютикс Аг | HUMANISED ANTIBODIES TO β-AMYLOID PEPTIDE |
EP2240495B1 (en) | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
EP2303332B1 (en) | 2008-07-15 | 2014-12-31 | Genentech, Inc. | Anthracycline conjugates, process for their preparation and their use as antitumor compounds |
WO2012174001A1 (en) | 2011-06-13 | 2012-12-20 | Abgenomics Cooperatief U.A. | Anti-psgl-1 antibodies and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406867B1 (en) * | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
WO2001064710A2 (en) * | 2000-02-29 | 2001-09-07 | Progenics Pharmaceuticals, Inc. | Sulfated ccr5 peptides for hiv-1 infection |
PL365758A1 (en) * | 2000-12-29 | 2005-01-10 | Savient Pharmaceuticals,Inc. | Specific human antibodies for selective cancer therapy |
KR20030091953A (en) * | 2000-12-29 | 2003-12-03 | 사비언트 파마슈티컬즈 인코퍼레이티드 | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
-
2004
- 2004-06-30 RU RU2006102571/13A patent/RU2006102571A/en not_active Application Discontinuation
- 2004-06-30 MX MXPA06000253A patent/MXPA06000253A/en unknown
- 2004-06-30 EP EP04777349A patent/EP1646401A4/en not_active Withdrawn
- 2004-06-30 AU AU2004256113A patent/AU2004256113A1/en not_active Abandoned
- 2004-06-30 CN CNA2004800249112A patent/CN1897970A/en active Pending
- 2004-06-30 JP JP2006518747A patent/JP2007527393A/en active Pending
- 2004-06-30 BR BRPI0411944-4A patent/BRPI0411944A/en not_active IP Right Cessation
- 2004-06-30 CA CA002531283A patent/CA2531283A1/en not_active Abandoned
- 2004-06-30 WO PCT/US2004/021099 patent/WO2005005455A2/en active Search and Examination
- 2004-06-30 KR KR1020067000219A patent/KR20060107501A/en not_active Application Discontinuation
-
2005
- 2005-12-12 IL IL172511A patent/IL172511A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1897970A (en) | 2007-01-17 |
RU2006102571A (en) | 2007-08-20 |
EP1646401A4 (en) | 2007-07-18 |
EP1646401A2 (en) | 2006-04-19 |
CA2531283A1 (en) | 2005-01-20 |
WO2005005455A3 (en) | 2006-02-16 |
KR20060107501A (en) | 2006-10-13 |
WO2005005455A2 (en) | 2005-01-20 |
AU2004256113A1 (en) | 2005-01-20 |
MXPA06000253A (en) | 2007-03-08 |
IL172511A0 (en) | 2006-04-10 |
JP2007527393A (en) | 2007-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313336A (en) | Pacifier for use in a user's mouth | |
HUP0300951A2 (en) | Ethylenedicysteine(ec)-drug conjugates, preparations and methods for tissue-specific disease imaging | |
DK1053256T3 (en) | Antibodies to Death Receptor 4 (DR4) and Applications thereof | |
BRPI0411944A (en) | specific human antibodies | |
DE69841322D1 (en) | HEPATITIS C RECEPTOR PROTEIN CD81 | |
Michel | Self-cure in infections of Trichostrongylus retortaeformis and its causation | |
Lesnicar | A prospective study of viral hepatitis A and the question of chronicity | |
DE3862017D1 (en) | PHARMACEUTICAL PREPARATION FOR TINEA PEDIS TREATMENT. | |
BR9612422A (en) | Recombinant viral pseudo-particles, composition, use of pseudo-particles, and process of in vitro stimulation of cytotoxic t responses of lymphocytes from individuals affected by viral or tumor infections. | |
Bernard et al. | NK Cells in Protection from HIV Infection | |
BR0210486A (en) | Protein, recombinant polypeptide, nucleic acid sequence and vector, cultured cell, nucleotide primer, purified antibody, immunogenic, vaccine and pharmaceutical compositions, screening process for molecules likely to inhibit growth of major leishmania, use of an acid probe nucleic acid, one or more inhibitors of protein disulfide isomerases and bacitracin or zinc bacitracin, in vitro diagnostic method of a parasitic infection responsible for leishmaniasis and diagnostic kit for carrying out the method | |
ATE249227T1 (en) | USE OF FUCOSILATED SIALILATED N-ACETYL-LACTOSAMINE CARBOHYDRATE STRUCTURES TO INHIBIT BACTERIAL ADHESION | |
Stone et al. | Case 10-2013: a 30-year-old man with fever, myalgias, arthritis, and rash | |
Yoeli et al. | Cyclical transmission of Plasmodium berghei in the laboratory | |
MAZZUR et al. | New specificity of Australia antigen | |
Ogidi et al. | Covid-19 vaccination: the pros and cons | |
Toyohama et al. | Kaposi's sarcoma in a human immunodeficiency virus-negative patient treated with corticosteroid for idiopathic thrombocytopenic purpura | |
Violand et al. | Permeabilization of Ehrlich ascites tumor cells by human serum | |
Sharma | Medical Biotechnology | |
Nchinda et al. | PO 8590 Comparative analysis of IGG responses to recombinant qβ phage displayed MSP3 and UBO5 in dual HIV/malaria-co-infected adults | |
Tibenderana | Outbreak of Marburg Virus in northwest Tanzania: Unleashing health emergency | |
Bergman et al. | Thyroid gland | |
Kawiak et al. | Cytochemical characterization of mouse L1210 leukemia | |
Martin et al. | History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications | |
Warren et al. | PR 879-317A enhances in vitro immune activity of peripheral blood mononuclear cells from patients with Down syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |